Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Jeffrey Hellman(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Rodrigo Maegawa(Eastern Maine Medical Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Haesook T. Kim(Dana-Farber Cancer Institute), Karen Francoeur(Dana-Farber Cancer Institute), Jens Rueter(Jackson Laboratory), Adam Boruchov(St. Francis Medical Center), Alyssa Nicotra(Dana-Farber Cancer Institute), Peter Sportelli(CDG Therapeutics (United States)), Eric D. Jacobsen(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Laura Stampleman, Josie Bazemore(Dana-Farber Cancer Institute), Alexandra Savell(Dana-Farber Cancer Institute), Hari P. Miskin(CDG Therapeutics (United States))
Cited by 115
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890